ERBB2 and neoplasm: One hundred six patients were found to have HER2 amplification on tumor tissue analysis on the FoundationOne, Oncomine Comprehensive Assay, or Ion Torrent AmpliSeq Comprehensive Cancer platforms, and 24 patients were found to have HER2 amplifications on cfDNA analysis using Guardant360 technology (Fig 1).